(Graphic) K. Franklin/Science
Those databases will illuminate studies of human variation worldwide, in part because the great genomic diversity in Africans can uncover spurious links to medical conditions, explains Concepcion Nierras, an NIH Common Fund geneticist. For example, in Europeans a rare variant of a gene for a low-density lipoprotein that contributes to high cholesterol seemed to raise the risk of heart disease. But Fatumo and his colleagues found that among Africans, the variant was common even in those who did not have heart disease, suggesting it may not have clinical relevance. The
Nature paper uncovered 54 such variants that now need re-evaluation.
How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis healthaffairs.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healthaffairs.org Daily Mail and Mail on Sunday newspapers.
Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference
Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week s HIV Research for Prevention (HIV R4P) Virtual Conference.
The Phase I studies, led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), found both of two gel-based products well-tolerated, with higher doses of the active drugs likely required to provide protection from HIV and other sexually transmitted infections (STIs).
NYU dental professor nets $1 9M grant for research drbicuspid.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drbicuspid.com Daily Mail and Mail on Sunday newspapers.
January 29, 2021 at 2:13 pm
A single-shot coronavirus vaccine made by Johnson & Johnson is 85 percent effective at preventing severe disease and death, even against new variants of the virus, the company announced in its interim analysis January 29.
The vaccine didn’t fare as well at preventing more moderate cases of COVID-19, particularly in Latin America and South Africa, where variants that spread more easily have arisen. Depending on location, the shot was only 72 percent to 57 percent effective against moderate to severe bouts of the illness.
Other vaccines, particularly the two mRNA vaccines that have emergency use authorization in the United States, have reported levels of overall efficacy of up to 95 percent against the coronavirus (